What Pediatric Child Hospital Jesus does

Ospedale Pediatrico Bambino Gesù (OPBG) is a non-profit pediatric hospital and research institution located in Rome, Italy, and the largest pediatric clinic and pediatric research center in Europe. Founded in 1924 and affiliated with the Holy See, it operates as an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) and holds JCI Academic Medical Center accreditation (since 2015, reaffirmed in 2024) and ISO 9001:2015 certification from DNV. The hospital delivers comprehensive pediatric care across four sites — Gianicolo (headquarters), San Paolo (research campus), Palidoro, and Santa Marinella — with an estimated 1,200+ beds and between 1,001 and 5,000 employees, serving children from newborns through adolescents across general and specialty disciplines including oncohematology, cardiology, transplant surgery, neurology, rheumatology, and genetics.

OPBG's research infrastructure includes a Biobank holding approximately 40,000 biological samples from 8,900 subjects across 18 ICD10 categories, integrated into the European BBMRI-ERIC federated platform, and a clinical trials unit running studies such as the Dompé Phase 2 intranasal NGF trial for spastic cerebral palsy. Proprietary research capabilities include CAR-T cell therapy development for pediatric leukemia under Prof. Franco Locatelli, ADAR2 RNA editing research for osteosarcoma, genomic identification of ultra-rare disease mutations (e.g., CDC42/NOCARH syndrome under Dr. Marco Tartaglia), and CRISPR-based molecular scissors approaches for thalassemia and sickle cell anemia. The hospital hosts Orphanet Italia, coordinates Italian participation in 20 European Reference Networks for rare diseases, and maintains JACIE accreditation for hematopoietic stem cell transplantation.

The business model is multi-stream and government-anchored. The majority of revenue is generated through reimbursement from Italy's Servizio Sanitario Nazionale (SSN) for inpatient, outpatient, surgical, transplant, and diagnostic services. Secondary streams include donations and 5x1000 tax designations via Fondazione Bambino Gesù Onlus, sponsored clinical trials and research grants from pharmaceutical partners (e.g., Dompé), and international patient services. Pricing for SSN-covered services follows public reimbursement rates with standard co-pays or exemptions, while international and research-funded services operate outside the SSN tariff structure. Patient acquisition occurs through SSN referral pathways, emergency department access, outpatient clinics (phone, online portal, or walk-in), and targeted international referral channels, with no traditional sales motion or external investor ownership given the Holy See parent structure.

Name

Pediatric Child Hospital Jesus

Legal name

Ospedale Pediatrico Bambino Gesù

Website

https://ospedalebambinogesu.it

Company type

Private

Founded year

1924

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ospedale Pediatrico Bambino Gesù is a non-profit pediatric hospital and IRCCS research center in Rome, affiliated with the Holy See and the largest of its kind in Europe. It delivers comprehensive pediatric clinical care across four sites while conducting translational research in oncohematology, rare diseases, genomics, and cell and gene therapies.

Ownership category

akta.pro rank

Product category

Pediatric Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Children’s Hospitals & Pediatric Health Systems (HLAFAJAG)

akta.pro secondary industries

Children’s Hospitals (Acute Care) (HLAFAAAI), Pediatric Specialty Care Centers (e.g., cardiology, oncology, neurology) (HLAFAJAH)

Keywords

• Pediatric hospital services
• Pediatric clinical research
• Rare disease treatment
• Pediatric oncology care
• Genomic medicine research

Headquarters

HQ city

Roma

HQ country

Italy

HQ region

Europe

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. National Health Service (SSN) Reimbursement: As a public hospital within Italy's national health system, the majority of revenue comes from SSN reimbursements for hospital services, diagnostic tests, surgeries, transplants, and outpatient care provided to patients covered by the Italian public health system.
2. Donations and Philanthropy: The hospital raises funds through donations (Dona ora campaigns), the 5 per mille (5x1000) tax designation program, and contributions to Fondazione Bambino Gesù Onlus. Donations support research projects, patient accommodation, and advanced therapies.
3. Clinical Research and Grants: The hospital conducts sponsored clinical trials and receives research grants as an IRCCS, contributing to revenue through collaborations with pharmaceutical companies (e.g., Dompé study on intranasal NGF for cerebral palsy) and participation in national and European research programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Ospedale Pediatrico Bambino Gesù is the largest pediatric hospital and pediatric research center in Europe, providing comprehensive general and specialized pediatric clinical care across all medical and surgical disciplines for children from newborns to 18 years, including emergency services, day hospital, day surgery, transplants, and outpatient care. As a designated IRCCS, it integrates translational research with clinical practice, including CAR-T cell therapy, genomic diagnostics, a 40,000-sample research biobank, and participation in 20 European Reference Networks for rare diseases.

Product overview

Ospedale Pediatrico Bambino Gesù is a comprehensive pediatric hospital offering a unified portfolio of healthcare services. The core offerings include general and specialized pediatric care across multiple disciplines (oncohematology, rheumatology, neurology, cardiology, surgery, and transplants), supported by in-house laboratory analysis services and blood collection centers. Digital patient services include online appointment booking, medical report access, and MyVue Cloud for radiology image viewing. The hospital operates a research biobank (approximately 40,000 samples) and clinical trials unit, with participation in the Orphanet Italia rare disease network. Additional support services include pediatric school, pain management clinic, and a 24/7 poison control center. The hospital holds JCI academic medical center accreditation and ISO 9001:2015 certification.

Differentiator

Problem solved

Functional benefit

Products and services

• Pediatric Hospital Services Comprehensive pediatric healthcare services including general and specialized pediatric care across all medical and surgical disciplines (oncohematology, rheumatology, neurology, cardiology, surgery), emergency services (Pronto Soccorso), day hospital, day surgery, surgical procedures, and organ transplants (heart, liver, bone marrow) for children from newborns to 18 years.
• Laboratory Analysis Services Diagnostic laboratory services covering clinical chemistry, hematology, coagulation, endocrinology, pharmacology, allergology, autoimmunity, and molecular biology testing for pediatric patients, accessible without appointment through Centro Prelievi.
• Blood Collection Centers (Centri Prelievi) Blood sample collection facilities at San Paolo, Palidoro, and Santa Marinella locations providing pediatric-specific phlebotomy services mostly without appointment, serving patients of all ages including neonates and adults.
• Research Biobank (Biobanca del Bambino Gesù) Biological sample collection, processing, storage, and distribution service for biomedical research purposes, conserving approximately 40,000 biological samples from 8,900 subjects across 18 ICD10 categories, focused on rare, complex, genetic, and onco-hematological diseases.
• Orphanet Italia Italian branch of the international rare disease network hosting a comprehensive database of rare diseases, orphan drugs, expert centers, and ORPHAcode classification, serving 41 countries worldwide and connecting OPBG with 20 European Reference Networks.
• Clinical Trials Unit (U.O.C. Trials) Clinical research unit conducting and managing clinical trials for pediatric treatments and therapies, including sponsored studies with pharmaceutical companies (e.g., Dompé Phase 2 trial for intranasal NGF in spastic cerebral palsy) and participation in national and European research programs.
• MyVue Cloud - Radiology Image Portal Online platform enabling patients to view and consult radiological images including MRI, CT scans, and ultrasounds produced during outpatient appointments, provided free of charge.
• Pediatric School Educational services for hospitalized children to continue their schooling during treatment, including dedicated teachers and learning materials to support continued education during inpatient stays.
• Pain Management Clinic (Ospedale senza Dolore) Specialized outpatient clinic for pediatric pain assessment and treatment, providing comprehensive pain management services for children.
• Poison Control Center (Centro Antiveleni) Emergency hotline service for poisoning and intoxication cases, available 24/7 at +39 06 6859 3726, providing immediate pediatric toxicology consultation and guidance.

Quantifiable outcome

• 80% of children with neoplasms in Italy are cured, with survival rates directly attributed to investments in pediatric oncology research
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Dompé (biopharmaceutical company)minorStrategic or Co-development Partner · 30 March 2026Dompé, a biopharma company with operations in Italy and the U.S., enrolled the first patient in a Phase 2 study of intranasal NGF (Cenegermin-bkbj) for spastic cerebral palsy at Agostino Gemelli IRCCS University Hospital. OPBG is listed as a participating center in this multi-center trial across 10 Italian sites enrolling 60 children.
• Orphanet (INSERM-led international consortium)coreStrategic or Co-development PartnerOPBG hosts Orphanet Italia, the national node of the international rare disease network involving 41 countries. Orphanet provides a comprehensive database of rare diseases, expert centers, and orphan drugs, and OPBG contributes expertise and coordinates Italian participation in the European Reference Networks (ERN).
• BBMRI-ERIC (Biobanking and BioMolecular Resources Research Infrastructure)coreStrategic or Co-development PartnerOPBG's research biobank is integrated into the European BBMRI-ERIC network, participating in the Federated Platform project for cross-border data interoperability, European Health Data Space implementation, and external proficiency testing programs (IBBL).
• European Reference Networks (ERN) - 20 networkscoreStrategic or Co-development PartnerOPBG participates in 20 European Reference Networks for rare diseases, which connect expert centers across Europe to share knowledge, develop guidelines, and improve care for rare disease patients. ERNs cover conditions including rare cancers, rare bone disorders, rare liver diseases, and rare immunological disorders.
• Bambino Gesù Children's Hospital Research TeamcoreStrategic or Co-development PartnerResearchers led by Dr. Andrea Del Fattore and Prof. Angela Gallo from OPBG demonstrated ADAR2 enzyme restoration as a therapeutic approach for osteosarcoma. The multi-model study showed ADAR2 activation inhibits tumor growth and enhances chemotherapy sensitivity, representing a translational research collaboration within the hospital.
• Fondazione Bambino Gesù OnluscoreGTM or Marketing PartnerThe hospital's charitable foundation receives donations and fundraising contributions (including EUR 110,000 raised by a patient's family for CAR-T research) and coordinates philanthropy, 5 per mille campaigns, and patient support programs.
• DNV (Det Norske Veritas)minorOthersDNV is the international certification body that audits and certifies OPBG's ISO 9001:2015 quality management system on an annual basis, with full recertification every three years.
• International HLH research networkminorStrategic or Co-development PartnerOPBG coordinates international clinical trials for HLH (Hemophagocytic Lymphohistiocytosis) treatments and the experimental use of emapalumab, working with centers globally including the Karolinska Institutet (Sweden) and Great Ormond Street Hospital (UK).

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Texas Children's Hospital: One of the largest US pediatric hospitals with extensive research programs in cancer, genetics, and heart disease — directly comparable to OPBG in scale, multi-site operations, and translational research intensity.
• Cincinnati Children's Hospital Medical Center: A leading US pediatric academic medical center known for CAR-T cell therapy development, gene therapy trials, and translational research — directly comparable to OPBG's onco-hematology and rare disease programs.
• Children's Hospital of Philadelphia (CHOP): A top-ranked US pediatric hospital and research institute with strong CAR-T and cell therapy programs and a large international patient footprint — directly comparable to OPBG in pediatric specialty depth, research intensity, and complex-case referral pipeline.
• Royal Children's Hospital Melbourne: A leading Australian pediatric academic hospital with strong research output and a large catchment — directly comparable to OPBG in mission, multi-specialty scope, and academic medical center status.
• Great Ormond Street Hospital for Children (GOSH): A leading UK pediatric research hospital with international referral flows, active in CAR-T and rare disease research — directly comparable to OPBG in scope, mission, and academic medical center status. OPBG explicitly collaborates with GOSH on HLH research.
• Hôpital Necker-Enfants Malades (AP-HP, Paris): France's largest pediatric hospital and a leader in pediatric genetics, rare diseases, and transplantation — directly comparable to OPBG as a European pediatric academic medical center with strong research and rare-disease focus.
• Hospital Sant Joan de Déu (Barcelona): A major European pediatric teaching hospital with a strong research institute (IRSJD), active in rare disease networks and pediatric clinical trials — directly comparable to OPBG in size, scope, and Mediterranean European positioning.

Emerging players

• Baylor College of Medicine / Texas Children's Cancer Center: An academic pediatric oncology powerhouse with strong CAR-T and cell therapy programs. Comparable to OPBG's onco-hematology research portfolio, particularly Prof. Locatelli's CAR-T and stem cell transplantation programs.

Broad incumbents

• IRCCS Ospedale San Raffaele: A leading Italian IRCCS with translational research infrastructure and significant pediatric-adjacent activity. Comparable to OPBG as a same-country Italian research hospital, though not pediatric-focused, making it a broad incumbent rather than a direct competitor.

Others

• Boston Children's Hospital:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/bambinogesu
• YouTubeyoutube.com/channel/UCxLIDM3aVL-6QXh1a5dQ1LA
• Facebookfacebook.com/ospedalebambinogesu
• LinkedInlinkedin.com/company/ospedale-pediatrico-bambino-gesu
• Instagraminstagram.com/orphanetitalia

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pediatric Child Hospital Jesus